Benzinga | Aug 16, 2021 08:48AM EDT

Wedbush Maintains Neutral on IGM Biosciences, Raises Price Target to $82

Wedbush analyst Robert Driscoll maintains IGM Biosciences (NASDAQ:IGMS) with a Neutral and raises the price target from $77 to $82.